Press Release

Category Added in a WPeMatico Campaign

Business Wire20 April 2026

AECOM announces planned dates for second quarter fiscal 2026 earnings results and conference call

DALLAS–(BUSINESS WIRE)–AECOM (NYSE: ACM), the trusted global infrastructure leader, today announced that it intends to issue its second quarter fiscal…
Read More »
Business Wire20 April 2026

Blackstone Secured Lending Announces First-Quarter 2026 Earnings Release and Conference Call

NEW YORK–(BUSINESS WIRE)–Blackstone Secured Lending Fund (NYSE: BXSL) (the “Company”) announced today that it will host its first-quarter 2026 investor…
Read More »
Cision PR Newswire20 April 2026

Automotive Dashcam Market worth $6.55 billion by 2033| MarketsandMarkets™

DELRAY BEACH, Fla., April 20, 2026 /PRNewswire/ — According to MarketsandMarkets™, the automotive dashcam market is projected to grow from USD…
Read More »
Cision PR Newswire20 April 2026

Guide Sets a New Standard for Industrial Thermography at Hannover Messe 2026

HANNOVER, Germany, April 20, 2026 /PRNewswire/ — On April 20, Hannover Messe 2026 officially opened at the Exhibition Grounds Hannover…
Read More »
Cision PR Newswire20 April 2026

SKYWORTH Dominates the 139th Canton Fair with Revolutionary OLED, RGB, and QD-MiniLED Smart TVs, Redefining Global Display Technology

GUANGZHOU, China, April 20, 2026 /PRNewswire/ — On April 15th, the 139th China Import and Export Fair (Canton Fair), co-hosted…
Read More »
Cision PR Newswire20 April 2026

IGT Appoints Mark Wadley Incoming President of Land-Based Gaming

Will Lead an Integrated, End-to-End Gaming Business Spanning Product, Commercial, and Operational Functions LAS VEGAS, April 20, 2026 /PRNewswire/ —…
Read More »
Cision PR Newswire20 April 2026

SOLAI Limited Files 2025 Annual Report on Form 20-F

AKRON, Ohio, April 20, 2026 /PRNewswire/ — SOLAI Limited (NYSE: SLAI) (previously traded under “BTCM”) (“SOLAI” or the “Company”), a technology-driven…
Read More »
Cision PR Newswire20 April 2026

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial Building on the existing…
Read More »
Business Wire20 April 2026

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer

Applications are supported by the Phase 3 KEYNOTE-B15 results, which showed that KEYTRUDA plus Padcev demonstrated a statistically significant and…
Read More »
Business Wire20 April 2026

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer

Applications are supported by the Phase 3 KEYNOTE-B15 results, which showed that KEYTRUDA plus Padcev demonstrated a statistically significant and…
Read More »

Previous page Next page